News

Multiconsult's 2025 Q2 Performance: A Tale of Growth and Strategy

Multiconsult's 2025 Q2 Performance: A Tale of Growth and Strategy

Multiconsult's 2025 Second Quarter Overview

Multiconsult ASA reported a moderate performance in the second quarter of 2025, while demonstrating a notable uptick in merger and acquisition (M&A) activities within a generally stable market environment. The company's EBITA for the quarter stood at NOK 67.4 million, leading to a cumulative EBITA of NOK 257.8 million for the first half of the year, marking an EBITA margin of 4.8%. The overall EBITA margin for the first six months reached 8.8%. However, the second quarter's EBITA reflected a year-on-year decrease of 17.6%, adjusting for calendar variations.

Financial Highlights from Q2 2025

Despite facing challenges, Multiconsult witnessed robust activity across most segments, primarily fueled by higher billing rates. However, the company was slightly hindered by reduced capacity, a result of fewer working days. Net operating revenues amounted to NOK 1,415.9 million, reflecting an organic revenue growth of 4.2%, adjusted for calendar effects and acquisitions. The quarterly billing ratio recorded a slight decline to 72.9%, down by 0.9 percentage points compared to the same period last year. The order intake for the quarter was NOK 1.539 billion, contributing to a solid order backlog of NOK 4.575 billion, setting the stage for the next growth phase of Multiconsult.

Key Metrics to Note

  • Net operating revenues saw a minor decrease, reducing by 0.6% year-on-year.
  • Organic revenue growth held steady at 4.2% after adjustments.
  • EBITA of NOK 67.4 million represented a margin of 4.8%.
  • The EBITA margin, adjusted for calendar effects, hit 10.2%.
  • Billing ratio landed at 72.9%, slightly down from 73.8% last year.
  • Order backlog remains strong, supporting future activities.
  • Full-time equivalents (FTE) increased by 6.6%, rising to 3,762 employees.
  • Net profit stood at NOK 40.3 million with earnings per share at NOK 1.45.

Growth through Strategic Acquisitions

The announcement of the acquisition of the ViaNova group has been a highlight for the company. This strategic move aims to bolster Multiconsult's competence in the transport and mobility sector, marking one of the most significant acquisitions since Erichsen & Horgen in 2021. CEO Grethe Bergly expressed enthusiasm about the synergy between the companies, noting that ViaNova's culture of innovation resonates well with Multiconsult's values. The integration is expected to propel growth and enhance their market position significantly.

Looking Ahead: Market Outlook

Multiconsult’s market outlook remains stable, supported by a strong order backlog. Although the overall EBITA performance in the second quarter fell short compared to the previous year, factors such as four fewer working days played a role in this dip. The team is developing strategies to counteract lower billing ratios and rising operational costs. The successful refinancing of credit facilities, amounting to NOK 2.5 billion, further strengthens the company’s financial position as it moves forward.

Frequently Asked Questions

What were the key financial highlights for Multiconsult in Q2 2025?

In Q2 2025, Multiconsult experienced net operating revenues of NOK 1,415.9 million and an EBITA of NOK 67.4 million, reflecting a moderate performance.

How did the ViaNova acquisition impact Multiconsult?

The acquisition enhances Multiconsult's capabilities in transport and mobility, positioning it for stronger future growth.

What challenges did Multiconsult face in Q2 2025?

The company dealt with reduced capacity due to fewer working days and a lower billing ratio, which impacted overall EBITA performance.

How does Multiconsult's growth strategy look moving forward?

Multiconsult aims to leverage strategic acquisitions and a robust order backlog to fuel future growth while managing operational costs effectively.

What is Multiconsult's outlook for the remainder of 2025?

The market outlook remains stable, with a strong order backlog supporting high levels of activity moving forward.

About The Author

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.

Top 10 Most Recent News Articles

Regeneron Faces Class Action Over Tumultuous Trial Results

Updated Category News Views 3

Regeneron's Meltdown: A Bitter Pill for Investors Let’s dive headlong into the mess Regeneron Pharmaceuticals (NASDAQ:REGN) finds itself in—a classic nightmare scenario for investors. News broke like an old valve bursting, and suddenly, the market's love for Regeneron ran ice-cold. Who's to blame this time? Well, you might want to point a finger at the failed Phase 3...

Continue Reading
Big Wins at Americas Cardroom's $15M Venom Series

Updated Category News Views 0

High Stakes and Huge Paydays: The Venom Breakdown Alright, folks, here's a tale of how the cards fell in one of the most electrifying poker standoffs at Americas Cardroom. With prize pools clocking in at a staggering $15.095 million, the Dual Mystery Bounty Venoms really stacked the chips high. From the gritty, bustling halls of the internet to the proverbial green-felt...

Continue Reading
Drunk Angel Celebrates First Year in Crystal Jewelry

Updated Category News Views 2

One Year Down, A Unique Path Forward It's been a year since Drunk Angel jumped into the online jewelry scene, and they're setting themselves apart in their own glittery lane. Imagine starting a brand that's not just about pretty trinkets, but about linking those tiny treasures to timeless traditions. They've got their sights set on blending the deep tales of gemstones...

Continue Reading
Celebree Elevates Early Ed with New Certification Push

Updated Category News Views 0

A New Standard in Early Childhood Education In the cutthroat world of childcare and early education, just meeting the state standards ain't cutting it anymore. Celebree School, known for its infant, toddler, and preschool programs, is shaking things up with its 'Celebree Certified' initiative, setting a brand-new benchmark for teacher readiness that's far beyond the usual...

Continue Reading
Lida Group Expands Global Modular Construction Services

Updated Category News Views 5

Modular Construction's Expanding Footprint Behold Lida Group—a titan in the world of modular construction—taking ambitious strides into the global arena, reaching from the sand dunes of Saudi Arabia to the bustling corridors of the United Nations. If you haven't been paying attention, now's the time to get your head in the game. Their expansion isn't just about...

Continue Reading
Jollibee and DreamWorks Unite for Cultural Celebration

Updated Category News Views 1

Jollibee Partners with DreamWorks Animation Never thought I’d see the day: Jollibee, that familiar face of fast food, teaming up with the creative juggernaut DreamWorks Animation. They’re calling it a celebration of friendship and Filipino culture, wrapped up neatly in the context of a flick called Forgotten Island. Set to sizzle in theaters on September 25, 2026,...

Continue Reading
Dentsply Sirona Faces Insider Troubles: An Investor Call

Updated Category News Views 3

Are Dentsply Sirona Insiders on Thin Ice? The stock market's a tumultuous sea, and right now, it seems like some of those at the helm of Dentsply Sirona Inc. might be rocking the boat a bit too much. Let me tell you, navigating these corporate storms isn't for the faint-hearted. The latest noise coming from Halper Sadeh LLC suggests that some directors and officers over...

Continue Reading
DoorDash Speeds Up Gifting: Same-Day Delivery Wins

Updated Category News Views 3

Transforming Urgent Gift-Giving with Local Delivery Ever found yourself scrambling for a last-minute gift when time seems to be slipping away? That's where DoorDash steps up, changing the game with their same-day delivery options. In the fast-paced world we're living in, folks aren't just leaning on DoorDash for takeout anymore. They're pushing it as a lifeline for...

Continue Reading
Supernova SPAC Lawsuit: Settlement Proposed, $3M on Table

Updated Category News Views 3

Legal Clouds Over Supernova's SPAC Adventure Alright, folks, buckle up, because whenever you mix SPACs and lawsuits, you're in for a roller coaster. Supernova Partners Acquisition Company, Inc. stands right at the heart of a class action lawsuit, and it's been cooking ever since the court in Delaware gave it a nudge forward. Settlement Talk: What's on the Table? So here's...

Continue Reading
York Space Systems Faces Investor Lawsuit Over Claims

Updated Category News Views 1

Allegations Stir the Pot: York Space Systems Under Fire Now we're sailing into choppy waters with York Space Systems (YSS). There's a full-blown ruckus stirring as investors take aim at the company, thanks to a class action lawsuit alleging securities fraud. The legal beagles from Glancy Prongay Wolke & Rotter LLP are spearheading this effort, claiming that York pulled...

Continue Reading

Top 5 Most Recently Viewed Articles

Neumora Therapeutics: Upcoming Financial Results and Insights

Updated Category News Views 123

Neumora Therapeutics to Announce Financial Results Neumora Therapeutics, Inc. (Nasdaq: NMRA), a pioneering biopharmaceutical firm, is gearing up to share its financial outcomes for the second quarter of a future year. The conference call is set for 4:30 p.m. ET on a Wednesday, and this event aims to deliver important updates regarding their business and strategic...

Continue Reading
Exciting Insights into Claudin 6 Targeted Therapy for Cancer

Updated Category News Views 165

Introduction to TORL BioTherapeutics and TORL-1-23 TORL BioTherapeutics, LLC is leading the way in developing innovative cancer treatments, particularly focusing on antibody-drug conjugates that target Claudin 6. Their flagship product, TORL-1-23, has shown significant potential in recent clinical trials specifically aimed at patients with Claudin 6 positive cancers. This...

Continue Reading
Understanding Plasma Biomarkers for Liver Health in Youth

Updated Category News Views 118

Plasma Biomarkers and Liver Health in Adolescents Recent research has unveiled an exciting advancement in pediatric medicine regarding liver health in adolescents, particularly among Latino youth facing obesity. The study, conducted by the Children's Hospital Los Angeles, led by Principal Investigator Michael Goran, PhD, has explored the potential of plasma-based...

Continue Reading
Gruma's Market Control: A Look at Price Fixing in Mexico

Updated Category News Views 119

Cofece Ruling on Gruma's Price Fixing Authority In a significant decision that has set the stage for future pricing strategies, Mexico's antitrust authority, Cofece, announced that Gruma, a prominent player in the corn flour and tortilla market, has the ability to fix prices. This conclusion was reached following a comprehensive investigation, which revealed a lack of...

Continue Reading
Coloplast A/S Unveils Strong Financial Performance for 2024/25

Updated Category News Views 190

Coloplast A/S Interim Financial Highlights for 2024/25 Coloplast A/S has recently announced its interim financial results for the period from 1 October 2024 to 30 June 2025. This report unveils the company's impressive organic growth and highlights its strategies for maintaining its market position. Remarkable Growth Figures The latest results showcase an organic growth...

Continue Reading